GE Healthcare PRESS RELEASE GE HEALTHCARE LAUNCHES LULLABY

							                                                            GE Healthcare




PRESS RELEASE

GE HEALTHCARE LAUNCHES LULLABY™ PHOTOTHERAPY SYSTEM
FOR INFANT JAUNDICE TREATMENT AT MEDICA CONGRESS
•   GE EXPANDS MATERNAL-INFANT CARE (MIC) AND IMAGING PRODUCT PORTFOLIO
•   DESIGNED AND DEVELOPED IN INDIA FOR MARKETS WORLDWIDE
•   AIMS TO BRING TECHNOLOGY ON PAR WITH DEVELOPED COUNTRIES
•   EARLY DETECTION AND TREATMENT OF JAUNDICE IN NEWBORNS


DÜSSELDORF, NOVEMBER 14, 2007 - GE Healthcare, the US$17 billion healthcare and life sciences
solutions business of global major General Electric Company (GE), today launches Lullaby™; a new
blue Compact Fluorescent Lamp (CFL) based Phototherapy System for the treatment of indirect
hyperbilirubinemia, or jaundice in newborns. The Lullaby Phototherapy System will be on display
during this week’s MEDICA Congress, Düsseldorf, Germany.

The Lullaby Phototherapy System, designed and developed at GE’s R&D Centre in India, is part of
their “In India, for India” program to make high end technology more affordable, reliable and more
accessible to larger segments of society. GE Healthcare plans to export the Lullaby Phototherapy
System to Europe, Latin America, Middle East and Asia Pacific.

According to Omar Ishrak, President and CEO of GE Healthcare’s Clinical Systems business, “GE’s
clinical partnerships, technology leadership and continuous investment in healthcare solutions allow
us to invite healthcare’s top physicians ‘to the drawing board’ to re-imagine healthcare solutions.
Together, we’re developing innovative healthcare solutions to help address some of today’s most
pressing healthcare issues such as improving access to quality care in rural communities and
developing regions of the world and, in developed regions, shifting to an ‘early health’ model of
care.”

“As a part of our overall business strategy, GE Healthcare plans to tie-up and acquire products in
varied segments to become a complete solutions provider in the healthcare and life sciences space.
With our recent tie up with Phoenix, we have now started manufacturing these products in India to
expand our Maternal-Infant care portfolio. We plan to explore further opportunities to tap other
potential segments,” said V Raja, President and CEO, GE Healthcare South Asia.




Page 1 of 4
Press Release/GE Healthcare/November 14, 2007
                                                             GE Healthcare




According to various neonatal experts, jaundice is one of the most common conditions requiring
medical attention in newborns. There are 133 million newborn babies in the world diagnosed with
jaundice annually. About 8-10% of term infants and 80% of pre-term infants annually are required
to undergo phototherapy for 3-5 days either at hospital or home.

GE Healthcare, a leading healthcare and life sciences solutions provider, aims to bring high quality,
advanced technology Maternal-Infant Care systems such as the Lullaby Phototherapy system to
market, to address the growing needs of mothers and babies. GE is currently expanding its
Maternal-Infant Care (MIC) and imaging products.

GE’s Lullaby Phototherapy System, a unique phototherapy system, combines high levels of clinical
performance and with a simple flexible design. Lullaby delivers phototherapy healing anywhere – in
the Neonatal ICU, Pediatrics ICU, and in a Well Baby Nursery. The Lullaby Phototherapy System is
exceptionally durable and easy to maintain. It meets all International Electro Technical Commission
and Electro Magnetic Compatibility regulatory standards for safe operation and has incorporated
new guidelines like the recommendations from the American Academy of Pediatrics. The long life of
its robust high intensity lamps – upwards of 1,000 hours – makes Lullaby Phototherapy System a
reliable performer, day after day, patient after patient.

Lullaby Phototherapy System along with GE’s Billiblanket High Output system, can effectively
provide double intensive phototherapy treatment. GE offers a complete portfolio of phototherapy
products for treatment of hyperbilirubinemia. From an expectant mother’s first visit to her
obstetrician, to the days after mother and baby leave the hospital, GE assists healthcare
professionals in supporting the specialized needs of patients and families across the entire
maternal-infant continuum.


About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new
age of patient care. Our expertise in medical imaging and information technologies, medical
diagnostics, patient monitoring systems, performance improvement, drug discovery, and
biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine
new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to
the fullest.

GE Healthcare's broad range of products and services enable healthcare providers to better
diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our




Page 2 of 4
Press Release/GE Healthcare/November 14, 2007
                                                              GE Healthcare




vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-
symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE
Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare
employs more than 46,000 people committed to serving healthcare professionals and their patients
in more than 100 countries. For more information about GE Healthcare, visit our website at
www.gehealthcare.com.

Contact
Rudolf Beyenburg
Director Marketing and Corporate Communications
T + 49 (0) 212 2802 111
Rudolf.Beyenburg@ge.com




Page 3 of 4
Press Release/GE Healthcare/November 14, 2007
                                                             GE Healthcare




Notes to Editor:
High levels of bilirubin can occur in the blood called hyperbilirubinemia. These high levels can be
dangerous to a baby. It is important to obtain periodic blood samples to check the bilirubin levels
and, if necessary, to treat jaundice to ensure the healthy development of your child. Phototherapy
with or without a Billiblanket is the most common form of treatment for neonatal jaundice. This
treatment is used for a few days until the liver is mature enough to handle the bilirubin on its own.
Some “normal” jaundice will disappear within a week or two without treatment. Other babies will
require treatment because of the severity of the jaundice, the cause of the jaundice, or how old the
baby is when jaundice appears.

Phototherapy (light treatment) is the process of using light to eliminate bilirubin in the blood. A
baby's skin and blood absorb these light waves. These light waves are absorbed by the baby's skin
and blood and change bilirubin into products, which can pass through their system. For over 30
years, phototherapy treatment in the hospital has been provided by a row of lights or a spotlight
suspended at a distance form a baby. This would provide light shining directly on an undressed
baby (with diaper on) whose eyes would need protection from the light with soft eye patches
applied. Today, advancements in technology have led to a new phototherapy system, which gives
effective treatment without the inconveniences of conventional phototherapy treatment.

Billiblanket phototherapy is a developmental care product. This gives high intensity cold
phototherapy for the treatment of jaundice without the need of eye to be covered, baby to be
naked, day night cycle affected, reducing insensible waterloss and overall reducing stress to the
baby during phototherapy.




Page 4 of 4
Press Release/GE Healthcare/November 14, 2007